Riquent failure hits La Jolla hard
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Negative results from La Jolla's Riquent (abetimus) Phase III interim efficacy analysis, which have derailed development of the compound, are also causing the firm to substantially reduce personnel and other operating expenses while it considers strategic options, including winding down the business or selling the company. On Feb. 12, just weeks after La Jolla sold an option to license rights for the lupus nephritis therapy to BioMarin, an independent data monitoring board taking a scheduled peek at the ASPEN data said the trial had no chance of showing efficacy. Riquent is La Jolla's only clinical-stage compound 1(Pharmaceutical Approvals Monthly January 2009, p. 22).
You may also be interested in...
BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial
With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.